3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Renal Cell
4
Multiple Myeloma
3
Gastrointestinal Stromal Tumors
3
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Gastrointestinal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Cyclophosphamide
13
Rituximab
11
obinutuzumab
6
fludarabine phosphate
6
Prednisone
6
Magnetic Resonance Spectroscopy
6
ibrutinib
5
fludarabine
5
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Lenalidomide
5
Etoposide
5
Doxorubicin
5
Biopsy
5
tocilizumab
4
Whole-Body Irradiation
4
venetoclax
3
polatuzumab vedotin
3
glofitamab
3
acalabrutinib
3
Vincristine
3
Mycophenolic Acid
3
Leukapheresis
3
Filgrastim
3
Cytarabine
3
Cyclosporine
3
Busulfan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Sunitinib
×
30 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled